Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309864 | 0.84 | CXCR5 (1.00) | CXCR5ERAP1 | |
| SCHEMBL3312127 | 0.83 | CXCR5 (0.51) | CXCR5 | |
| SCHEMBL3309481 | 0.80 | CXCR5 (0.74) | CXCR5 | |
| SCHEMBL3309626 | 0.79 | CXCR5 (0.64) | CXCR5 | |
| SCHEMBL485737 | 0.76 | DGAT2 (0.43) | CXCR5 | |
| SCHEMBL3310747 | 0.75 | CXCR5 (1.00) | CXCR5 | |
| SCHEMBL4111119 | 0.74 | CXCR2 (0.47) | CXCR5 | |
| SCHEMBL28785337 | 0.73 | CXCR5 (0.72) | CXCR5 | |
| SCHEMBL485831 | 0.72 | DGAT2 (0.42) | CXCR5 | |
| SCHEMBL3303886 | 0.72 | CXCR5 (0.62) | CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| CN-101679346-A | substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI AVENTIS | 2010-03-24 | — | — | CN | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | CXCR5 1/4885ERAP1 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.